Development of Bengali version of a questionnaire assessing impact of hyperuricemia on quality of life

Saha, Sangita; Chattopadhyay, Rajat; Das, Satadal; Sarkar, Paulami; Nayak, Chintamani; Bhar, Koushik; Misra, Pankhuri; Chattopadhyay, Abhijit; Ghosh, Priyanka; Ganguly, Shirshendu; Mukherjee, Shyamal Kumar; Koley, Munmun; Saha, Subhranil

doi:10.4103/jss.jss_114_20

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Hyperuricemia quality of life (HUQLQ) is a validated patients' self-administered questionnaire in the Bengali language, consisting of 19 items and framed within five components: concern; inconvenience in daily activities; professional restriction; mood and temperament; treatment hazards. 22 Items are derived from the GAQ-2 questionnaire. Each item is measured on a 5-point (0-4) Likert scale: the higher the score, the greater is the problem.…”

Section: Secondarymentioning

confidence: 99%

Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU. Methods This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed. Results The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F 1, 56 = 13.833, p <0.001), HUQLQ scores (F 1, 56 = 32.982, p <0.001) and MYMOP-2 profile scores (F 1, 56 = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups. Conclusion IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU. Trial registration CTRI/2019/10/021503; UTN: U1111–1241–1431.

show abstract

Section: Secondarymentioning

confidence: 99%